Erratum: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|17|3048-3048

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.17, 2015-09, pp. : 3048-3048

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice

By                

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 107-113

Spandidos Publications

Access to resources Recommend Favorite

Effects of Angiotensin II Type 1 Receptor Blocker on Blood Pressure Variability and Cardiovascular Remodeling in Hypertensive Patients on Chronic Peritoneal Dialysis

By  

Nephron Clin Pract, Vol. 112, Iss. 1, 2009-04 ,pp. : c31-c40

Karger

Access to resources Recommend Favorite

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 539-546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Calcium Channel Blocker versus Angiotensin II Receptor Blocker in Autosomal Dominant Polycystic Kidney Disease

By  

Nephron Clin Pract, Vol. 99, Iss. 1, 2005-01 ,pp. : c18-c23

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite